CNK2 promotes cancer cell motility by mediating ARF6 activation downstream of AXL signalling.
Guillaume SerweDavid KachanerJessica GagnonCédric PlutoniDriss LajoieEloïse DuraméMalha SahmiDamien GarridoMartin LefrançoisGeneviève ArseneaultMarc K Saba-El-LeilSylvain MelocheGregory EmeryMarc TherrienPublished in: Nature communications (2023)
Cell motility is a critical feature of invasive tumour cells that is governed by complex signal transduction events. Particularly, the underlying mechanisms that bridge extracellular stimuli to the molecular machinery driving motility remain partially understood. Here, we show that the scaffold protein CNK2 promotes cancer cell migration by coupling the pro-metastatic receptor tyrosine kinase AXL to downstream activation of ARF6 GTPase. Mechanistically, AXL signalling induces PI3K-dependent recruitment of CNK2 to the plasma membrane. In turn, CNK2 stimulates ARF6 by associating with cytohesin ARF GEFs and with a novel adaptor protein called SAMD12. ARF6-GTP then controls motile forces by coordinating the respective activation and inhibition of RAC1 and RHOA GTPases. Significantly, genetic ablation of CNK2 or SAMD12 reduces metastasis in a mouse xenograft model. Together, this work identifies CNK2 and its partner SAMD12 as key components of a novel pro-motility pathway in cancer cells, which could be targeted in metastasis.
Keyphrases
- tyrosine kinase
- cell migration
- biofilm formation
- epidermal growth factor receptor
- squamous cell carcinoma
- binding protein
- induced apoptosis
- small cell lung cancer
- papillary thyroid
- genome wide
- pseudomonas aeruginosa
- protein protein
- single cell
- machine learning
- cancer therapy
- small molecule
- squamous cell
- deep learning
- cell therapy
- men who have sex with men
- cystic fibrosis
- hiv testing
- hepatitis c virus
- drug delivery
- candida albicans
- cell death
- cell cycle arrest
- living cells